Roche prices cancer drug at $17K a month

Roche has priced its cancer treatment Rozlytrek at $17,050 per month, about half the cost of a similar drug sold by Eli Lilly and Bayer, according to STAT.

Rozlytrek, approved Aug. 15, targets solid tumors that show rare genetic defects called NTRK gene fusions and ROS1-positive non-small cell lung cancer. 

Eli Lilly and Bayer's drug Vitrakvi is priced at $32,800 per month. It also treats tumors with NTRK gene fusions. 

More articles on pharmacy:
CMS to cover CAR-T therapy nationwide
Colombia fines Pfizer $25K for drug price inflation
Jefferson Healthcare opens retail specialty pharmacy

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers